Navigation Links
NIH funds investigation of inhaled lung cancer treatment
Date:4/12/2011

April 11, 2011 (BRONX, NY) Just as inhaling cigarette smoke can cause lung cancer, inhaling medication may treat it. Two researchers at Albert Einstein College of Medicine of Yeshiva University have received a five-year, $2.4 million grant from the National Institutes of Health to clinically develop an inhaled therapy for lung cancer to be used before the cancer becomes malignant and spreads.

The grant recipients are Roman Perez-Soler, M.D., professor of medicine and associate director of clinical research at Albert Einstein Cancer Center; and Yiyu Zou, Ph.D., associate professor of medicine. Dr. Perez-Soler is also chair of oncology at Montefiore Medical Center.

Lung cancer is the leading cause of cancer mortality among men and women in the U.S. Each year, more than 220,000 are diagnosed and about 150,000 people die from the disease. The average five-year survival rate is only 15 percent, largely because nearly 80 percent of cases are diagnosed after the cancer has spread from the lungs to other organs in the body. Drs. Perez-Soler and Zou will take advantage of the fact that, for many years, the disease is confined to the bronchial epithelium (surface cells of the airways), where it lingers and develops in a premalignant state.

The research project involves inhaling a drug called 5-azacytidine to target the bronchial epithelium. 5-azacytidine is a demethylating agent, meaning it strips off methyl groups that have bound to genes and rendered them inactive. Since removing methyl groups can reactivate genes that suppress tumors, drugs such as 5-azacytidine can potentially treat a number of different types of cancers.

The first two years of the federally-funded study will focus on a mouse model of premalignant lung cancer, to determine what dose is likely to be safe and effective in humans. In years three through five, researchers will conduct a Phase I "feasibility and proof of principle" study in which patients with advanced non-small cell lung cancer (the most common type), and who no longer respond to standard therapy, will inhale 5-azacytidine. Albert Einstein College of Medicine has filed a patent application related to this research, which is available for licensing to partners interested in further testing and developing this treatment.

The ultimate aim of the research is to intervene with inhaled 5-azacytidine at an earlier, precancerous stage, when vital genes have been silenced but cancer has not yet developed. Using the therapy in this way it might prevent lung cancer from developing in people with a history of cigarette smoking. According to the Centers for Disease Control and Prevention, there are about 46 million adult smokers in the U.S.


'/>"/>

Contact: Kim Newman
sciencenews@einstein.yu.edu
718-430-3101
Albert Einstein College of Medicine
Source:Eurekalert

Related biology news :

1. Cystic Fibrosis Foundation funds Marshall research
2. NSF funds study of landscape restoration effects on Pennsylvania stream
3. Keck Foundation funds work on tiny, implantable computers to restore lost brain functions
4. FDA funds pediatric trial testing genetically reprogrammed HSV to treat cancer
5. NIH funds Center of Excellence for Molecular Hematology at Cincinnati Childrens
6. $1.5M grant funds research aimed at reducing strokes in children with sickle cell disease
7. NIH funds center at Arizona State to battle infectious diseases
8. French national research agency funds PREDIMOL project
9. NHGRI funds development of third generation DNA sequencing technologies
10. $22.5 million grant funds international study of membrane proteins
11. NSF funds innovative approach to biomimetic nanofiber bone regeneration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2016)... CHICAGO , April 13, 2016  IMPOWER physicians ... are setting a new clinical standard in telehealth ... By leveraging the higi platform, IMPOWER patients can ... weight, pulse and body mass index, and, when they ... quick and convenient visit to a local retail location ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
(Date:3/15/2016)... 15, 2016 --> ... Transparency Market Research "Digital Door Lock Systems Market - Global ... 2023," the global digital door lock systems market in terms ... and is forecast to grow at a CAGR of 31.8% ... and medium enterprises (MSMEs) across the world and high industrial ...
Breaking Biology News(10 mins):
(Date:4/27/2016)... ... April 27, 2016 , ... Cambridge Semantics, the ... technology, today announced that it has been named to The Silicon Review’s “20 Fastest ... and other markets, Cambridge Semantics serves the needs of end users facing some of ...
(Date:4/27/2016)... and RESEARCH TRIANGLE PARK, N.C. , ... UTHR ) announced today that Martine Rothblatt ... Therapeutics will provide an overview and update on the ... Annual Health Care Conference. The presentation will ... a.m. Eastern Time, and can be accessed via a ...
(Date:4/27/2016)... ... April 27, 2016 , ... Global Stem Cells Group CEO ... is the founder of GSCG affiliate Kimera Labs in Miami. , In 2004, Ross ... stem cell transplantation for hematologic disorders and the suppression of graft vs. host disease ...
(Date:4/26/2016)... (PRWEB) , ... April 26, 2016 , ... ... today announced that Ardy Arianpour has joined the company as Chief Business Officer. ... experience bringing innovative genomic technologies to market, was most recently Chief Commercial Officer ...
Breaking Biology Technology: